Delivering therapy |

A new option for patients with solid tumors​

Get in Touch Find a Physician

Intravenous (IV) Chemotherapy

Circulates chemotherapy through the bloodstream, exposing the entire body to the drug1,2

Trans-Arterial Micro-Perfusion (TAMP™)

Delivers chemotherapy directly near the tumor, limiting total body exposure3-6

Potential TAMP Benefits3,4,5

Targeted Delivery

Chemotherapy is delivered near the site of cancer

Improved Tolerability

Localized treatment reduces drug exposure to the rest of the body

Get Back to Normal

Potential to resume activities limited during IV chemotherapy

TAMP is an Innovative Drug-Delivery Platform Designed for Targeted Chemotherapy Delivery3-7

  • Uses the RenovoCath®, an FDA-cleared device, to concentrate the chemotherapy drug directly near the tumor​
  • Potentially maximizes local drug exposure while reducing the systemic toxicities often seen with IV chemotherapy​
  • Offers the potential to reduce side effects and improve tolerability for patients with solid tumors, such as pancreatic, lung, and sarcoma​
  • May be incorporated at any point in the overall cancer treatment plan​ ​

TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer

  • Read More

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

  • Read More

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

  • Read More

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

  • Read More

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

  • Read More

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

  • Read More

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

  • Read More

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

  • Read More

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

  • Read More

Take the Next Step

Your doctor will determine if TAMP is right for you and how this approach may fit within your overall treatment plan.

Find a Physician

References

  1. https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy.html
  2. Maehira H, et al. Oncology Letters. 30, 579. https://doi.org/10.3892/ol.2025.15325.
  3. Pishvaian M, et al. ESMO World Congress on Gastrointestinal Cancer; June 28-July 1, 2023; Barcelona, Spain.
  4. Hatoum H, et al. Oncologist. Volume 29, Issue 8, August 2024, Pages 690–698, https://doi.org/10.1093/oncolo/oyae178.
  5. Farsad K, et al. JVIR. 2024;35(7):1043-1048.
  6. Novelli PM, et al. Cancer Chemother Pharmacol. 2026;96:91. doi:10.1007/s00280-026-04939-0.
  7. https://www.onclive.com/view/new-jersey-patients-receiving-firstof- its-kind-catheter-based-pancreatic-cancer-treatment 

 

MKT-2168 Rev A